Search

A recent study conducted at the Hebrew University of Jerusalem has focused on the early detection of ovarian cancer (OC), which is often diagnosed at a late stage. The researchers explored the use of FLJ22447 lncRNA as a molecular biomarker for OC. They developed cyclopentane-modified FIT-PNAs (cpFIT-PNAs) to detect this RNA biomarker in living OC cells and cancer-associated fibroblasts (CAFs). The combination of cpFIT-PNAs with a cell-penetrating peptide (CLIP6) showed promising results in sensing FLJ22447 lncRNA and reducing cell viability. This research highlights the potential for theranostic applications of these molecules in the future. [Extracted from the article]

A new study conducted by researchers at Uppsala University provides new findings on Staphylococcus aureus, a bacterium that causes infections. The study focuses on the antibiotic fusidic acid (FA), which is commonly used to treat Staphylococcus aureus infections. The researchers used cryo-EM structures to examine the ribosome of Staphylococcus aureus in complex with mRNA, tRNA, EF-G, and FA. The study reveals new details about the ribosome and its interactions with FA, which could inform future drug discovery efforts. The research was supported by various organizations and foundations. [Extracted from the article]

A recent preprint abstract discusses the structures of the Staphylococcus aureus ribosome inhibited by fusidic acid (FA) and its derivative, fusidic acid cyclopentane (FA-CP). FA is an antibiotic used to treat Staphylococcus aureus infections, and it inhibits protein synthesis by binding to elongation factor G (EF-G) and preventing its release from the ribosome. The study used cryo-EM to determine the structures of the S. aureus ribosome in complex with mRNA, tRNA, EF-G, and FA or FA-CP. The structures revealed new details about the S. aureus ribosome and provide insights for future drug discovery. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]

Keywords: Alicyclic Hydrocarbons; Amino Acids; Arginine; Basic Amino Acids; Cancer; Cycloparaffins; Cyclopentanes; Diamino Amino Acids; Drugs and Therapies; Enzymes and Coenzymes; Essential Amino Acids; Genetics; Health and Medicine; Hydrocarbons; Methyltransferases; Oncology; Organic Chemicals; Patent Application; Risk and Prevention; Therapeutics; Therapy EN Alicyclic Hydrocarbons Amino Acids Arginine Basic Amino Acids Cancer Cycloparaffins Cyclopentanes Diamino Amino Acids Drugs and Therapies Enzymes and Coenzymes Essential Amino Acids Genetics Health and Medicine Hydrocarbons Methyltransferases Oncology Organic Chemicals Patent Application Risk and Prevention Therapeutics Therapy 1420 1420 1 08/21/23 20230825 NES 230825 2023 AUG 22 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A patent application by the inventors Brehmer, Dirk (Freiburg, DE); Greway, Anthony T. (Bound Brook, NJ, US); Guo, Yue (North Wales, PA, US); Haddish-Berhane, Nahor (Doylestown, PA, US); Lauring, Josh (Towson, MD, US); Mannens, Geert S.J. (Lier, BE); Packman, Kathryn Elizabeth (Newton, MA, US); Quinn, Hillary Joy Millar (Perkiomenville, PA, US); Wu, Tongfei (Hever, BE); Xie, Hong (Dresher, PA, US); Zhou, Junguo (Flemington, NJ, US), filed on January 26, 2023, was made available online on August 3, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Methods Of Treating Cancer Using Prmt5 Inhibitors. There is thus a strong need for novel treatment regimens involving PRMT5 inhibitors for the treatment or prevention of cancer. [Extracted from the article]

This correlation turns PRMT5 into an important small molecule drug target against cancer and other diseases. There is thus a strong need for novel treatment regimens involving PRMT5 inhibitors for the treatment or prevention of cancer. Keywords: Alicyclic Hydrocarbons; Amino Acids; Arginine; Basic Amino Acids; Business; Cancer; Cycloparaffins; Cyclopentanes; Diamino Amino Acids; Drugs and Therapies; Enzymes and Coenzymes; Essential Amino Acids; Genetics; Health and Medicine; Hydrocarbons; Janssen Pharmaceutica NV; Methyltransferases; Oncology; One-Carbon Group Transferases; Organic Chemicals; Pharmaceutical Companies; Risk and Prevention; Therapeutics; Therapy EN Alicyclic Hydrocarbons Amino Acids Arginine Basic Amino Acids Business Cancer Cycloparaffins Cyclopentanes Diamino Amino Acids Drugs and Therapies Enzymes and Coenzymes Essential Amino Acids Genetics Health and Medicine Hydrocarbons Janssen Pharmaceutica NV Methyltransferases Oncology One-Carbon Group Transferases Organic Chemicals Pharmaceutical Companies Risk and Prevention Therapeutics Therapy 1822 1822 1 03/24/23 20230228 NES 230228 2023 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Janssen Pharmaceutica NV (Beerse, Belgium) has been issued patent number 11571437, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]